Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs.
Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses’. Osel’s approach of repopulating the microbiome with beneficial bacteria helps restore healthy and protective microbiomes.
The primary focus of our work is women’s health, with indications including recurrent urinary tract infections and bacterial vaginosis. Our secondary focus is disorders of the gastrointestinal tract. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.
Osel is based in Mountain View, California.
Two products in clinical trials
Peter P. Lee, Founder and Executive Chairman
Dr. Lee is a pioneer in the field of emerging biotechnology, specializing in immunology and the Human Microbiome, with more than 20 years experience in basic and clinical investigations to bring products through the rigorous FDA approval process. Dr. Lee co-founded Osel in order to translate research into commercial products that harness the human microbiome. Dr. Lee is also Billy Wilder Endowed Professor and Chair of Immuno-Oncology at the City of Hope Comprehensive Cancer Center. Inventor of the bioengineered MucoCept technology, he has overseen the development of Osel’s portfolio of LBPs since 2002. A previous faculty member of Stanford University, Dr. Lee trained in hematology and immunology, where his goal has been to utilize the body’s immune system to treat cancer, infections, and other human conditions.
Dr. Lee has published more than 80 articles in peer-reviewed journals and received significant grant awards from the National Institutes of Health, US Department of Defense, and Stand Up To Cancer. He is an elected member of the American Society for Clinical Investigation, and recipient of the Department of Defense Era of Hope Scholar Award, American Cancer Society Research Scholar, and Damon Runyon Scholar Award.
Laurel A. Lagenaur, PhD, Director of Research
Dr. Lagenaur is Osel’s first employee and has led development of Osel’s Lactobacillus technology platform as the Director of Research. She has been the principal investigator on numerous research grants, including Osel’s first SBIR grant to develop MucoCept-HIV as a novel live microbicide to prevent HIV transmission in women.Dr. Lagenaur is a molecular biologist with extensive experience in virology and bacteriology and was a clinical microbiologist in both the human and veterinary fields. She received her doctorate in Microbiology and Immunology from Stanford University, and completed a post-doctoral fellowship at the University of California, San Francisco.
Tom Parks, PhD, Director of Product Development
Dr. Parks is a 25 year veteran of the pharmaceutical and biotech industries. He has served as the Director of Product Development since 2006, having joined Osel in 2002. He also oversees clinical operations and regulatory activities. ‘Prior to joining Osel, Dr. Parks served as the Director of Molecular Biology and Experimental Therapeutics at Cellegy Pharmaceuticals, where he established research and drug development programs in the areas of skin inflammation and gastrointestinal diseases, and at Boehringer Ingelheim Pharmaceuticals, where he spearheaded drug discovery programs in inflammation and autoimmune diseases and served on a number of compound development teams. Dr. Parks received his doctorate in physiology and pharmacology from UCSD and was a research fellow at Yale University.
Michael Cannon, Board Member
Mr. Cannon is a 40 year veteran of the life science industry with deep chemistry background and international senior management experience overseeing R&D, manufacturing, business development and operations. Mr. Cannon spent the majority of his career with SICOR Pharmaceuticals a generic manufacturer of bulk corticosteroids, anti-cancer drugs and anesthetics where he started off as a chemist, but subsequently took leadership roles including Chief Scientific Officer, Divisional President, Head of Business Development and Board of Director. In 2004, SICOR was sold to TEVA for $3.4 billion. Mr. Cannon represents Diamondhide (investment fund founded by Mr. Cannon, Mr. Carlo Salvi (Former CEO of SICOR) and couple other former SICOR senior management) and also serves as a member of the Scientific Advisory Board of Trevi Health Ventures, a medical device-focused investment fund. In addition to Osel, Mr. Cannon also serves on the Board of Directors for WaterStone Pharmaceuticals, a vertically integrated pharmaceutical company in Wuhan, China.
Sandy Chau, Board Member
Sandy Chau is the founder and Chairman of Suma Ventures. Mr. Chau has been a successful entrepreneur and investor, identifying major trends and actively participating in those trends either as entrepreneur or investor in multiple industries and multiple geographies. Mr. Chau received his Chemical Engineering degree at UC Berkeley, and became an early pioneer in the semiconductor industry in Silicon Valley where in early 1970s had started a semiconductor company, raised $15M USD venture capital, and subsequently sold company. From mid 70s until the 90s Mr. Chau split time between real estate and technology endeavors. He founded the AAMA (Asia America Multi-Technology Association) which has become Silicon Valley’s largest and most prominent organization bridging entrepreneurs, senior executives and investors doing business between Silicon Valley and Asia. He became an extremely successful real estate mogul in Greater China where he pioneered the department store concepts in China, and also subsequently became CEO of one of largest publicly traded real estate and construction development companies in the region. Mr. Chau shifted his assets and holdings from China to US commercial real estate, and through these investments in US had tremendous success. Mr. Chau then created Suma Ventures as a vehicle for channeling his technology investment activities where he has been actively leading investments over the last several years.
Robert Lee, Board Member
Dr. Robert P. Lee, a 30-year veteran of the computer industry, is Executive Chairman of Achievo Corporation. He is co-founder of the company in 2002 and served as its CEO from 2002 through 2008. Dr. Lee was also president and CEO of Accela, Inc., one of the leading government automation software companies in the U.S. Prior to that, Dr. Lee was president and CEO of Inxight Software, Inc. Prior to Inxight Software, he was chairman, president and CEO of Insignia Solutions plc, a software company he took public in 1995. Dr. Lee also served as Executive Vice President at Symantec Corporation where he led the acquisition and integration of many companies, including Norton Computing. He was Senior Vice President at Shared Medical Systems Corporation (now merged with Siemens), and earlier in his career held various technical and business management positions at IBM and Computer Sciences Corporation. Dr. Lee is a member of the board of directors and advisor to several companies. Dr. Lee was formerly chairman and president of Silicon Valley’s Asia America MultiTechnology Association (AAMA) for multiple terms. Dr. Lee received a bachelor’s degree from the University of California, Berkeley, and masters and doctorate degrees from the University of California, Los Angeles, all in computer science